Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomised, Double-blind, Double-dummy, Multi-centre, Comparative Parallel-group Study to Evaluate the Efficacy of Oral Rifamycin SV-MMX 400 mg b.i.d. vs. Rifamycin SV-MMX 600 mg t.i.d. vs. Placebo in the Treatment of Acute Uncomplicated Diverticulitis

Next Previous
X
Search
Trial Profile

A Randomised, Double-blind, Double-dummy, Multi-centre, Comparative Parallel-group Study to Evaluate the Efficacy of Oral Rifamycin SV-MMX 400 mg b.i.d. vs. Rifamycin SV-MMX 600 mg t.i.d. vs. Placebo in the Treatment of Acute Uncomplicated Diverticulitis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 07 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rifamycin (Primary)
  • Indications Diverticulitis
  • Focus Therapeutic Use
  • Sponsors Dr Falk Pharma

    • Most Recent Events

    • 25 Jul 2017 Status changed from recruiting to completed.
    • 06 Feb 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Mar 2017.
    • 30 May 2016 Planned End Date changed from 1 Dec 2015 to 1 Apr 2017.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top